Epidemiologic perspective on immune-surveillance in cancer

Current Opinion in Immunology

Volumn 23, Issue 2, 2011, Pages 265-271

  Cramer, Daniel W ^a   Finn, Olivera J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 6; MUCIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; B LYMPHOCYTE; CANCER IMMUNOLOGY; CANCER RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILDHOOD CANCER; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHATIC LEUKEMIA; OBESITY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; T LYMPHOCYTE; TUMOR IMMUNITY;

AGE DISTRIBUTION; AGE FACTORS; ANIMALS; CHRONIC DISEASE; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; NEOPLASMS;

EID: 79953107374     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2011.01.002     Document Type: Review

References (72)

1. Prehn R.T., Prehn L.M. The flip side of immune surveillance: immune dependency. Immunol Rev 2008, 222:341-356.
2. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008, 18:11-18.
3. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
4. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997, 80:1273-1283.
5. Frank S.A. Age of cancer incidence. Dynamics of Cancer: Incidence, Inheritance, and Evolution 2007, Princeton Press. H.A. Orr (Ed.).
6. Fulop T., Kotb R., Fortin C.F., Pawelec G., de Angelis F., Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci 2010, 1197:158-165.
7. Stewart S.A., Weinberg R.A. Telomeres: cancer to human aging. Annu Rev Cell Dev Biol 2006, 22:531-557.
8. Lustgarten J. Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 2009, 58:1979-1989.
9. Derhovanessian E., Maier A.B., Beck R., Jahn G., Hahnel K., Slagboom P.E., de Craen A.J., Westendorp R.G., Pawelec G. Hallmark features of immunosenescence are absent in familial longevity. J Immunol 2010, 185:4618-4624.
10. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
11. Wolin K.Y., Carson K., Colditz G.A. Obesity and cancer. Oncologist 2010, 15:556-565.
12. Fernandez-Riejos P., Najib S., Santos-Alvarez J., Martin-Romero C., Perez-Perez A., Gonzalez-Yanes C., Sanchez-Margalet V. Role of leptin in the activation of immune cells. Mediators Inflamm 2010, 2010:568343.
13. Dixit V.D. Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J Leukoc Biol 2008, 84:882-892.
14. Yang H., Youm Y.H., Vandanmagsar B., Rood J., Kumar K.G., Butler A.A., Dixit V.D. Obesity accelerates thymic aging. Blood 2009, 114:3803-3812.
15. Karlsson EA, Sheridan PA, Beck MA: Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol 2010, 184:3127-3133.
16. U.S.Department of Health and Human Services The Health Consequences of Smoking: A Report of the Surgeon General 2004, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
17. Botteri E., Iodice S., Bagnardi V., Raimondi S., Lowenfels A.B., Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. JAMA 2008, 300:2765-2778.
18. Bracci P.M., Holly E.A. Tobacco use and non-Hodgkin lymphoma: results from a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control 2005, 16:333-346.
19. Watters J.L., Park Y., Hollenbeck A., Schatzkin A., Albanes D. Cigarette smoking and prostate cancer in a prospective US cohort study. Cancer Epidemiol Biomarkers Prev 2009, 18:2427-2435.
20. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-265.
21. Takahashi H.K., Iwagaki H., Hamano R., Yoshino T., Tanaka N., Nishibori M. Effect of nicotine on IL-18-initiated immune response in human monocytes. J Leukoc Biol 2006, 80:1388-1394.
22. Zhou B., Yang L., Sun Q., Cong R., Gu H., Tang N., Zhu H., Wang B. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 2008, 121:501-508. e503.
23. Morris V. Space-time interactions in childhood cancers. J Epidemiol Community Health 1990, 44:55-58.
24. van Steensel-Moll H.A., Valkenburg H.A., van Zanen G.E. Childhood leukemia and infectious diseases in the first year of life: a register-based case-control study. Am J Epidemiol 1986, 124:590-594.
25. Vineis P., Miligi L., Crosignani P., Fontana A., Masala G., Nanni O., Ramazzotti V., Rodella S., Stagnaro E., Tumino R., et al. Delayed infection, family size and malignant lymphomas. J Epidemiol Community Health 2000, 54:907-911.
26. Abel U., Becker N., Angerer R., Frentzel-Beyme R., Kaufmann M., Schlag P., Wysocki S., Wahrendorf J., Schulz G. Common infections in the history of cancer patients and controls. J Cancer Res Clin Oncol 1991, 117:339-344.
27. West R.O. Epidemiologic study of malignancies of the ovaries. Cancer 1966, 19:1001-1007.
28. Newhouse M.L., Pearson R.M., Fullerton J.M., Boesen E.A., Shannon H.S. A case control study of carcinoma of the ovary. Br J Prev Soc Med 1977, 31:148-153.
29. Schiffman M.H., Hartge P., Lesher L.P., McGowan L. Mumps and postmenopausal ovarian cancer. Am J Obstet Gynecol 1985, 152:116-118.
30. McDuffie H.H., Pahwa P., McLaughlin J.R., Spinelli J.J., Fincham S., Dosman J.A., Robson D., Skinnider L.F., Choi N.W. Non-Hodgkin's lymphoma and specific pesticide exposures in men: cross-Canada study of pesticides and health. Cancer Epidemiol Biomarkers Prev 2001, 10:1155-1163.
31. Krone B., Kolmel K.F., Henz B.M., Grange J.M. Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 2005, 41:104-117.
32. Cramer D.W., Vitonis A.F., Pinheiro S.P., McKolanis J.R., Fichorova R.N., Brown K.E., Hatchette T.F., Finn O.J. Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control 2010, 21:1193-1201.
33. Jerome K.R., Domenech N., Finn O.J. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993, 151:1654-1662.
34. Ioannides C.G., Fisk B., Jerome K.R., Irimura T., Wharton J.T., Finn O.J. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993, 151:3693-3703.
35. Kao H., Marto J.A., Hoffmann T.K., Shabanowitz J., Finkelstein S.D., Whiteside T.L., Hunt D.F., Finn O.J. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001, 194:1313-1323.
36. Suzuki H., Graziano D.F., McKolanis J., Finn O.J. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005, 11:1521-1526.
37. Sorensen R.B., Andersen R.S., Svane I.M., Engell-Noerregaard L., Hadrup S.R., Balslev E., Andersen M.H., thor Straten P. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res 2009, 15:1543-1549.
38. Andersen RS, Sorensen RB, Ritter C, Svane IM, Becker JC, Thor Straten P, Andersen MH: Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol Immunother 2010.
39. Vella L.A., Yu M., Fuhrmann S.R., El-Amine M., Epperson D.E., Finn O.J. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci USA 2009, 106:14010-14015.
40. Leisenfelder S.A., Moffat J.F. Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity. J Virol 2006, 80:5577-5587.
41. Sanchez V., Spector D.H. Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles. J Virol 2006, 80:5886-5896.
42. Leisenfelder S.A., Kinchington P.R., Moffat J.F. Cyclin-dependent kinase 1/cyclin B1 phosphorylates varicella-zoster virus IE62 and is incorporated into virions. J Virol 2008, 82:12116-12125.
43. Dinse G.E., Umbach D.M., Sasco A.J., Hoel D.G., Davis D.L. Unexplained increases in cancer incidence in the United States from 1975 to 1994: possible sentinel health indicators?. Annu Rev Public Health 1999, 20:173-209.
44. Lambe M., Wuu J., Weiderpass E., Hsieh C.C. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control 1999, 10:43-49.
45. Layde P.M., Webster L.A., Baughman A.L., Wingo P.A., Rubin G.L., Ory H.W. The independent associations of parity, age at first full term pregnancy, and duration of breastfeeding with the risk of breast cancer. Cancer and Steroid Hormone Study Group. J Clin Epidemiol 1989, 42:963-973.
46. Rosenblatt K.A., Thomas D.B. Prolonged lactation and endometrial cancer. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1995, 24:499-503.
47. Whittemore A.S., Harris R., Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992, 136:1184-1203.
48. Collaborative Group on Hormonal Factors in Breast Cancer, ICRF Cancer Epidemiology Unit, Radcliffe Infirmary, Oxford, UK: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996, 347:1713-1727.
49. Le Vecchia C. Oral contraceptives and ovarian cancer: an update, 1998-2004. Eur J Cancer Prev 2006, 15:117-124.
50. Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Lindgren A., Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999, 10:277-284.
51. Agrawal B., Reddish M.A., Krantz M.J., Longenecker B.M. Does pregnancy immunize against breast cancer?. Cancer Res 1995, 55:2257-2261.
52. Cramer D.W., Titus-Ernstoff L., McKolanis J.R., Welch W.R., Vitonis A.F., Berkowitz R.S., Finn O.J. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1125-1131.
53. Pinheiro S.P., Hankinson S.E., Tworoger S.S., Rosner B.A., McKolanis J.R., Finn O.J., Cramer D.W. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010, 19:1595-1601.
54. Casagrande J.T., Louie E.W., Pike M.C., Roy S., Ross R.K., Henderson B.E. " Incessant ovulation" and ovarian cancer. Lancet 1979, 2:170-173.
55. Henderson B.E., Ross R.K., Judd H.L., Krailo M.D., Pike M.C. Do regular ovulatory cycles increase breast cancer risk?. Cancer 1985, 56:1206-1208.
56. McPherson C.P., Sellers T.A., Potter J.D., Bostick R.M., Folsom A.R. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 1996, 143:1195-1202.
57. Terry K.L., Titus-Ernstoff L., McKolanis J.R., Welch W.R., Finn O.J., Cramer D.W. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:30-35.
58. Erbagci A.B., Yilmaz N., Kutlar I. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women. Dis Markers 1999, 15:259-267.
59. Brinton L.A., Gridley G., Persson I., Baron J., Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997, 176:572-579.
60. Cramer D.W., Liberman R.F., Titus-Ernstoff L., Welch W.R., Greenberg E.R., Baron J.A., Harlow B.L. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999, 81:351-356.
61. Karageorgi S., Gates M.A., Hankinson S.E., De Vivo I. Perineal use of talcum powder and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2010, 19:1269-1275.
62. Cramer D.W., Welch W.R., Berkowitz R.S., Godleski J.J. Presence of talc in pelvic lymph nodes of a woman with ovarian cancer and long-term genital exposure to cosmetic talc. Obstet Gynecol 2007, 110:498-501.
63. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
64. Reuschenbach M., von Knebel Doeberitz M., Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009, 58:1535-1544.
65. Kitamura H., Honma I., Torigoe T., Hariu H., Asanuma H., Hirohashi Y., Sato E., Sato N., Tsukamoto T. Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients. Urology 2007, 70:38-42.
66. Brichory F.M., Misek D.E., Yim A.M., Krause M.C., Giordano T.J., Beer D.G., Hanash S.M. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001, 98:9824-9829.
67. Wurl P., Weigmann F., Meye A., Fittkau M., Rose U., Berger D., Rath F.W., Dralle H., Taubert H. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroenterol 1997, 32:1147-1151.
68. Jezersek B., Rudolf Z., Novakovic S. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients. Oncol Rep 2001, 8:77-81.
69. Wandall H.H., Blixt O., Tarp M.A., Pedersen J.W., Bennett E.P., Mandel U., Ragupathi G., Livingston P.O., Hollingsworth M.A., Taylor-Papadimitriou J., et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010, 70:1306-1313.
70. Raedle J., Oremek G., Welker M., Roth W.K., Caspary W.F., Zeuzem S. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 1996, 13:241-246.
71. Heneghan M.A., McCarthy C.F., Janulaityte D., Moran A.P. Relationship of anti-Lewis x and anti-Lewis y antibodies in serum samples from gastric cancer and chronic gastritis patients to Helicobacter pylori-mediated autoimmunity. Infect Immun 2001, 69:4774-4781.
72. Bosscher J.R., Gercel-Taylor C., Watkins C.S., Taylor D.D. Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients. Gynecol Oncol 2001, 81:138-143.